Search research articles
Contact Us
Filters
Showing results (161-170 of 173) with videos related to
Page
of 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
Patricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
Sandrine Faivre, Magaly Zappa, Valérie Vilgrain, et al.
The New England Journal of Medicine
|
February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
Eric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
Autophagy
|
November 6, 2021
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma <i>via</i> modulation of lysosomal functions
Sonia Brun, Eloïne Bestion, Eric Raymond, et al.
Investigational New Drugs
|
May 4, 2005
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
Charlotte van Kesteren, Anthe S Zandvliet, Mats O Karlsson, et al.
BMC Cancer
|
July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
The Lancet. Oncology
|
April 20, 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu, Ken Kato, Eric Raymond, et al.
JCO Precision Oncology
|
September 15, 2022
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies
Vladimir Lazar, Nicolas Girard, Eric Raymond, et al.
Neuroendocrinology
|
July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Eric Raymond, Matthew H Kulke, Shukui Qin, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 173) with videos related to
Sort By:
Page
of 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
Patricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
Sandrine Faivre, Magaly Zappa, Valérie Vilgrain, et al.
The New England Journal of Medicine
|
February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
Eric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
Autophagy
|
November 6, 2021
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma <i>via</i> modulation of lysosomal functions
Sonia Brun, Eloïne Bestion, Eric Raymond, et al.
Investigational New Drugs
|
May 4, 2005
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
Charlotte van Kesteren, Anthe S Zandvliet, Mats O Karlsson, et al.
BMC Cancer
|
July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
The Lancet. Oncology
|
April 20, 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu, Ken Kato, Eric Raymond, et al.
JCO Precision Oncology
|
September 15, 2022
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies
Vladimir Lazar, Nicolas Girard, Eric Raymond, et al.
Neuroendocrinology
|
July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Eric Raymond, Matthew H Kulke, Shukui Qin, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Page
of 18